News & Updates

Combining the programmed cell death ligand 1 (PDL-1) inhibitor avelumab with paclitaxel plus ramucirumab appears to be efficacious and safe in the second-line treatment of metastatic esophagogastric adenocarcinoma, as shown in the phase II nonrandomized RAP trial.

Low-dose calcium supplementation during pregnancy was noninferior to standard high-dose supplementation in preventing the risk of pre-eclampsia, according to two randomized clinical trials conducted in India and Tanzania.

Children who undergo cataract surgery appear to be at risk of having glaucoma later in life, according to a study.

In the treatment of older patients with nonvalvular atrial fibrillation (AF) who are considered ineligible for oral anticoagulants at the recommended therapeutic strength or the approved doses, the use of low-dose edoxaban helps reduce the risk of stroke or systemic embolism regardless of body weight, although this benefit comes with a slightly higher major bleeding events, according to the subgroup analysis of the phase III ELDERCARE‐AF trial.

For patients who have undergone coronary artery bypass graft, initiating treatment with sacubitril/valsartan early is safe and appears to improve outcomes, as shown in an open-label study.

An international team of experts has identified 13 promising biomarkers to predict cardiovascular disease (CVD) risk in patients with type 2 diabetes mellitus (T2DM), of which N-terminal pro-brain natriuretic peptide (NT-proBNP) has shown the highest predictive utility with highest strength of evidence.

Women with anaemia during their early pregnancy are at heightened risk of delivering prematurely and giving birth to neonates with low birth weight and small for gestational age, as shown in a study.